{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:25:16Z","timestamp":1767147916705,"version":"build-2238731810"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtn.2025.102697","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T16:00:32Z","timestamp":1756137632000},"page":"102697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rational design and applications of piperazine and cyclohexane ionizable lipids for PKU and SSADH deficiency"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0521-504X","authenticated-orcid":false,"given":"Jiyeon","family":"Son","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunjung","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joonyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyelim","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Eun","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungeun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeewon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seo-hyeon","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunhee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaeyoung","family":"Ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soonhwa","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunhye","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heechun","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyokyoung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaesung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byunghoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuebao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana D.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0896-718X","authenticated-orcid":false,"given":"Young Kee","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhou","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Uk","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102697_bib1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.1553","article-title":"Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102697_bib2","article-title":"A Route to Lipid ALC-0315: a Key Component of a COVID-19 mRNA Vaccine","volume":"28","author":"Saadati","year":"2022","journal-title":"Chemistry"},{"key":"10.1016\/j.omtn.2025.102697_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/bph.16262","article-title":"Cardiac side effects of RNA-based SARS-CoV-2 vaccines: Hidden cardiotoxic effects of mRNA-1273 and BNT162b2 on ventricular myocyte function and structure","volume":"181","author":"Schreckenberg","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102697_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102697_bib5","doi-asserted-by":"crossref","DOI":"10.34133\/bmr.0017","article-title":"Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics","volume":"28","author":"Lee","year":"2024","journal-title":"Biomater. Res."},{"key":"10.1016\/j.omtn.2025.102697_bib6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00204-024-03912-1","article-title":"Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model","volume":"99","author":"Ahn","year":"2025","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.omtn.2025.102697_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102697_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41586-024-07266-7","article-title":"Interim analyses of a first-in-human phase 1\/2 mRNA trial for propionic acidaemia","volume":"628","author":"Koeberl","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102697_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ph16081088","article-title":"From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics","volume":"16","author":"Korzun","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omtn.2025.102697_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47460-9","article-title":"Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria","volume":"15","author":"Baek","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102697_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtn.2023.06.023","article-title":"Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine-transcarbamylase deficiency model mice","volume":"33","author":"Yamazaki","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102697_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23318-2","article-title":"mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease","volume":"12","author":"Cao","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102697_bib13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7150\/thno.84291","article-title":"Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape","volume":"14","author":"Li","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2025.102697_bib14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102697_bib15","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102697_bib16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1124\/dmd.122.001194","article-title":"Systemic Exposure, Metabolism, and Elimination of [ 14 C]-Labeled Amino Lipid, Lipid 5, after a Single Administration of mRNA Encapsulating Lipid Nanoparticles to Sprague-Dawley Rats","volume":"51","author":"Burdette","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omtn.2025.102697_bib17","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1039\/D3TB00649B","article-title":"Rational design and combinatorial chemistry of ionizable lipids for RNA delivery","volume":"11","author":"Xu","year":"2023","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.omtn.2025.102697_bib18","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1021\/acs.nanolett.0c00596","article-title":"A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene Editing In Vivo","volume":"20","author":"Hajj","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2025.102697_bib19","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1007\/s12274-024-6575-8","article-title":"Piperazine-derived ionizable lipids for enhanced mRNA delivery and cancer immunotherapy","volume":"17","author":"Xu","year":"2024","journal-title":"Nano Res."},{"key":"10.1016\/j.omtn.2025.102697_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/cr60169a001","article-title":"The Stereoisomerism of Cyclohexane Derivatives","volume":"54","author":"Orloff","year":"1954","journal-title":"Chem. Rev."},{"key":"10.1016\/j.omtn.2025.102697_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00267-0","article-title":"Phenylketonuria","volume":"7","author":"van Spronsen","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omtn.2025.102697_bib22","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1002\/ana.10629","article-title":"Succinic semialdehyde dehydrogenase deficiency in children and adults","volume":"54","author":"Pearl","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2025.102697_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10556","article-title":"Novel piperazine-based ionizable lipid nanoparticles allow the repeated dose of mRNA to fibrotic lungs with improved potency and safety","volume":"8","author":"Kim","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102697_bib24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1080\/14756366.2021.1931861","article-title":"Piperazine skeleton in the structural modification of natural products: a review","volume":"36","author":"Zhang","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102697_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32281-5","article-title":"Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo","volume":"13","author":"Ni","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102697_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202415389","article-title":"Piperazine-Derived Bisphosphonate-Based Ionizable Lipid Nanoparticles Enhance mRNA Delivery to the Bone Microenvironment","volume":"64","author":"Yoon","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.omtn.2025.102697_bib27","doi-asserted-by":"crossref","first-page":"56157","DOI":"10.1039\/C7RA11005G","article-title":"Understanding the regioselectivity of Michael addition reactions to asymmetric divinylic compounds","volume":"7","author":"Navarro","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.omtn.2025.102697_bib28","article-title":"Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver","volume":"7","author":"Kim","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102697_bib29","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2025.102697_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2023.100161","article-title":"Lab-scale siRNA and mRNA LNP manufacturing by various microfluidic mixing techniques \u2013 an evaluation of particle properties and efficiency","volume":"12","author":"J\u00fcrgens","year":"2023","journal-title":"OpenNano"},{"key":"10.1016\/j.omtn.2025.102697_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122243","article-title":"Understanding structure activity relationships of Good HEPES lipids for lipid nanoparticle mRNA vaccine applications","volume":"301","author":"Goldman","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2025.102697_bib32","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102697_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202404684","article-title":"Discovery of Ketal-Ester Ionizable Lipid Nanoparticle with Reduced Hepatotoxicity, Enhanced Spleen Tropism for mRNA Vaccine Delivery","volume":"11","author":"Lv","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omtn.2025.102697_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115446","article-title":"Breaking the final barrier: Evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome","volume":"214","author":"Mrksich","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102697_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2024.108395","article-title":"Development and applications of lipid hydrophilic headgroups for nucleic acid therapy","volume":"74","author":"Ma","year":"2024","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.omtn.2025.102697_bib36","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","article-title":"Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d","volume":"8","author":"Chaudhary","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtn.2025.102697_bib37","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1021\/jacs.2c10670","article-title":"Iterative Design of Ionizable Lipids for Intramuscular mRNA Delivery","volume":"145","author":"Tilstra","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2025.102697_bib38","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102697_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102697_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/smsc.202300285","article-title":"Branching Ionizable Lipids Can Enhance the Stability, Fusogenicity, and Functional Delivery of mRNA","volume":"3","author":"Hashiba","year":"2023","journal-title":"Small Sci."},{"key":"10.1016\/j.omtn.2025.102697_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36978-z","article-title":"Amide-to-ester substitution as a stable alternative to N-methylation for increasing membrane permeability in cyclic peptides","volume":"14","author":"Hosono","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102697_bib42","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jps.2600730621","article-title":"Solubility parameter and hydrophilic\u2014lipophilic balance of nonionic surfactants","volume":"73","author":"Schott","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.omtn.2025.102697_bib43","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2025.102697_bib44","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/jbm.a.37705","article-title":"Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length","volume":"112","author":"Mrksich","year":"2024","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.omtn.2025.102697_bib45","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102697_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121596","article-title":"Structure\u2013activity relationships of pH-responsive and ionizable lipids for gene delivery","volume":"617","author":"Zou","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtn.2025.102697_bib47","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.3390\/cimb44100341","article-title":"Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application","volume":"44","author":"Mashima","year":"2022","journal-title":"CIMB"},{"key":"10.1016\/j.omtn.2025.102697_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2025.102697_bib49","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/acs.bioconjchem.6b00090","article-title":"Effects of Chemically Modified Messenger RNA on Protein Expression","volume":"27","author":"Li","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2025.102697_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202308447","article-title":"In Vitro Transcribed mRNA Immunogenicity Induces Chemokine-Mediated Lymphocyte Recruitment and Can Be Gradually Tailored by Uridine Modification","volume":"11","author":"Drzeniek","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omtn.2025.102697_bib51","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","article-title":"Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification","volume":"12","author":"Vaidyanathan","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102697_bib52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2017.09.041","article-title":"Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA","volume":"266","author":"Verbeke","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omtn.2025.102697_bib53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtn.2022.02.020","article-title":"Development of an mRNA replacement therapy for phenylketonuria","volume":"28","author":"Perez-Garcia","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102697_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102697_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39246-2","article-title":"Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing","volume":"14","author":"Brooks","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102697_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtn.2025.102697_bib57","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1021\/acs.molpharmaceut.2c00033","article-title":"Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells","volume":"19","author":"Ferraresso","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtn.2025.102697_bib58","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omtn.2025.102697_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202211420","article-title":"Optimizing Lipid Nanoparticles for Delivery in Primates","volume":"35","author":"Lam","year":"2023","journal-title":"Adv. Mater."}],"updated-by":[{"DOI":"10.1016\/j.omtn.2025.102735","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000}}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125002513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125002513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T02:02:08Z","timestamp":1766196128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125002513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2162253125002513"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102697","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design and applications of piperazine and cyclohexane ionizable lipids for PKU and SSADH deficiency","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102697"}}